Zhejiang DIAN Diagnostics Co., Ltd. signed equity transfer agreement to acquire 64% stake in Guangzhou Dihuixin Medical Devices Co., Ltd. from Hangzhou Digui Equity Investment Management Partnership Enterprise (Limited Partnership) for CNY 1 billion.
September 22, 2017
Share
Zhejiang DIAN Diagnostics Co., Ltd. (SZSE:300244) signed equity transfer agreement to acquire 64% stake in Guangzhou Dihuixin Medical Devices Co., Ltd. from Hangzhou Digui Equity Investment Management Partnership Enterprise (Limited Partnership) for CNY 1 billion on September 22, 2017. Zhejiang DIAN Diagnostics Co., Ltd. will fund the transaction via private placement with gross proceeds of not more than CNY 2.37 billion. As on April 22, 2018, Dian Diagnostics Group Co., Ltd. decided not to use money raised in private placements to fund the transaction and the transaction will now be funded by self financed funds of Dian Diagnostics Group Co., Ltd. After the transaction, Zhejiang DIAN Diagnostics Co., Ltd. will hold 64% stake and Hangzhou Digui Equity Investment Management Partnership Enterprise (Limited Partnership) will no longer hold any shares in Guangzhou Dihuixin Medical Devices Co., Ltd. As of December 31, 2016, Guangzhou Dihuixin Medical Devices Co., Ltd. reported total assets of CNY 678.82 million and total shareholder's equity of CNY 472.27 million. For 2016, Guangzhou Dihuixin Medical Devices Co., Ltd. reported operating revenue of CNY 910.05 million, operating profit of CNY 214.96 million and net profit of CNY 160.83 million. The transaction is subject to approval from China Securities Regulatory Commission.
Dean Diagnostic Technology Group Co., Ltd. is a company providing integrated solutions for medical diagnosis. The Company's main business involves inspection services, product services, health management, judicial expertise, contract research organization (CRO), cold chain logistics and other fields. The Company's business is mainly oriented to medical and health institutions at all levels, such as various general and specialized hospitals, community health service centers, township (town) health centers, physical examination centers, disease prevention and control centers, etc. The Company's products include Atomic Bomb in the field of liquid phase mass spectrometry, Hydrogen Bomb in the field of nucleic acid mass spectrometry, and Man-Made Satellite in the field of pathological diagnosis products and molecular diagnosis products, and others.
Zhejiang DIAN Diagnostics Co., Ltd. signed equity transfer agreement to acquire 64% stake in Guangzhou Dihuixin Medical Devices Co., Ltd. from Hangzhou Digui Equity Investment Management Partnership Enterprise (Limited Partnership) for CNY 1 billion.
DIAN DIAGNOSTICS GROUP CO.,LTD. 
